SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-023189
Filing Date
2024-02-29
Accepted
2024-02-29 16:41:19
Documents
17
Period of Report
2024-02-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K achv-20240228.htm   iXBRL 8-K 79581
2 EX-4.1 achv-ex4_1.htm EX-4.1 315573
3 EX-5.1 achv-ex5_1.htm EX-5.1 17764
4 EX-10.1 achv-ex10_1.htm EX-10.1 327617
5 EX-99.1 achv-ex99_1.htm EX-99.1 28932
6 GRAPHIC img9551541_0.jpg GRAPHIC 22486
  Complete submission text file 0000950170-24-023189.txt   1087358

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT achv-20240228.xsd EX-101.SCH 51753
18 EXTRACTED XBRL INSTANCE DOCUMENT achv-20240228_htm.xml XML 6342
Mailing Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021
Business Address 22722 29TH DR. SE SUITE 100 SEATTLE WA 98021 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

IRS No.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 033-80623 | Film No.: 24704531
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)